Gufic Biosciences Limited — Q1FY27 earnings call summary

Filed 17 August 2026 · Company audio recording

Capacity utilization still below 50%, requiring continued ramp-up to achieve margin targets
Indore plant capacity utilization expected to reach 40-45% by FY27 year-end, supporting export growth
New product launches in aesthetics (fillers by Q3 FY27) and nutraceuticals planned this year
Lyophilization to remain core (~50-60% capacity), liquids ~20%, complex injectables 20-30% by FY28
Pricing power expected to improve with direct field presence in emerging markets and IP ownership
Q1 FY27 EBITDA margin improved to 18.09% from 14.6% YoY, PAT margin rose to 11.56%
Margin expansion driven by higher capacity utilization, better product mix, and export market growth
GLP-1 CMO operations to ramp up from Q2, with significant traction expected in Q3 FY27